双膦酸盐疗法在骨质减少患者中的作用：一项系统评价。
Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review.
作者信息
Iqbal Shumaila M, Qamar Iqra, Zhi Cassandra, Nida Anum, Aslam Hafiz M
机构信息
Internal Medicine, University at Buffalo / Sisters of Charity Hospital, Buffalo, USA.
Internal Medicine, Brigham and Women's Hospital, Boston, USA.
出版信息
Cureus. 2019 Feb 27;11(2):e4146. doi: 10.7759/cureus.4146.
By contrast to clinical trials exploring osteoporosis, clinical trials specifically designed for the osteopenic population are limited. Thus, less clinical data are available regarding treatment benefits and cost-effectiveness of treating a patient population with a bone mass density in the osteopenic range (T-score between -1 and -2.5). In this article, we aimed to highlight this high-risk population with a low bone mass density (BMD) susceptible to high fracture risk by reviewing different national and international guidelines for treating osteopenia. The cost-effectiveness of the therapy for the above-mentioned patient population is also discussed. By reviewing different clinical trials, we have specifically highlighted the role of bisphosphonate therapy for fracture risk reduction and increment in bone mineral density (BMD) in patients with osteopenia.
与探索骨质疏松症的临床试验形成对比的是，专门为骨量减少人群设计的临床试验有限。因此，关于治疗骨量密度处于骨量减少范围内（T值在-1至-2.5之间）的患者群体的治疗益处和成本效益的临床数据较少。在本文中，我们旨在通过回顾不同的国家和国际治疗骨量减少的指南，突出这个骨量密度低、易发生高骨折风险的高危人群。还讨论了针对上述患者群体的治疗的成本效益。通过回顾不同的临床试验，我们特别强调了双膦酸盐治疗在降低骨量减少患者骨折风险和增加骨矿物质密度（BMD）方面的作用。
Zotero 插件